MHRA Approves Foundayo (Orforglipron): UK First in Europe
TL;DR: MHRA approved Lilly’s oral GLP-1 pill Foundayo (orforglipron) for UK weight loss and diabetes on 10 Aug 2026, first in Europe.
What Did the MHRA Approve on 10 August 2026?
On 10 August 2026, the MHRA authorised Foundayo (orforglipron), Eli Lilly's oral small-molecule GLP-1 receptor agonist, making the UK the first country in Europe to approve the tablet.[1] The licence covers two separate indications: weight management in adults with a BMI of 30 or above, or a BMI of 27–30 plus at least one weight-related comorbidity, taken alongside a reduced-calorie diet and increased physical activity; and improving glycaemic control in adults with insufficiently controlled type 2 diabetes.[1]
Unlike peptide-based oral semaglutide, which must be taken fasted with a small amount of water and no food or other medicines for 30 minutes afterward, Foundayo is a once-daily tablet that can be taken at any time of day with no food or water restrictions.[2] Lilly and the MHRA both frame this as a practical adherence advantage, since orforglipron's non-peptide chemistry does not require an absorption enhancer to survive the gut.
What Clinical Data Supported the Approval?
ATTAIN-1 randomised 3,127 adults with obesity, or overweight plus at least one weight-related condition, to once-daily oral orforglipron (6mg, 12mg or 36mg) or placebo for 72 weeks.[3] The highest dose produced a mean 11.2% reduction in body weight versus 2.1% with placebo (p<0.001); the 12mg and 6mg doses reduced weight by 8.4% and 7.5% respectively.[3] Waist circumference, systolic blood pressure, triglycerides and non-HDL cholesterol also improved relative to placebo.[3]
Source: New England Journal of Medicine, "Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment." doi:10.1056/NEJMoa2511774
ACHIEVE-3 randomised 1,698 adults with type 2 diabetes to orforglipron (12mg or 36mg) or oral semaglutide (7mg or 14mg) for 52 weeks.[4] The highest orforglipron dose cut A1C by 2.2 percentage points and body weight by 9.2%, versus 1.4 points and 5.3% with the highest oral semaglutide dose, meeting superiority on both the primary and key secondary endpoints.[4]
Source: The Lancet, reported via Eli Lilly investor news release, ACHIEVE-3 head-to-head trial results.
How Is Orforglipron Different From Oral Semaglutide and Retatrutide?
The three molecules sit on distinct chemical and regulatory tracks. Oral semaglutide is a peptide that requires SNAC, an absorption enhancer, plus strict fasting rules to survive digestion and reach the bloodstream; it activates only the GLP-1 receptor. Orforglipron is a non-peptide small molecule, chemically closer to a conventional tablet drug, that also activates only the GLP-1 receptor but without the same administration constraints.[3] Both are licensed medicines with MHRA marketing authorisations.
Retatrutide sits entirely outside this comparison. It is an injectable peptide that activates three receptors — GIP, GLP-1 and glucagon — rather than one, and it remains investigational: no oral formulation has been disclosed, and it carries no MHRA, FDA or EMA marketing authorisation anywhere.[5] Our retatrutide vs. tirzepatide vs. semaglutide comparison and oral semaglutide MHRA approval guide cover the mechanistic and regulatory distinctions in more depth. Foundayo's approval adds a third licensed oral GLP-1 option to a UK market that, as of this week, includes oral semaglutide (approved 11 June 2026) and now orforglipron, alongside AstraZeneca's elecoglipron still in Phase 2 development.
When Will Foundayo Be Available in the UK?
A Lilly spokesperson said Foundayo is expected to launch in the UK later in August 2026, available through private prescription and pharmacist-led Patient Group Direction (PGD) services, though no exact launch date or UK price has been confirmed.[2] The tablet is not currently available on the NHS. NICE guidance on NHS use is due on 18 November 2026, following the same review pathway that oral semaglutide went through earlier this year.[2]
Does This Affect Retatrutide or UK Peptide Research?
No. This is an MHRA marketing-authorisation decision for a licensed prescription medicine, made under the branded-drug licensing framework. It has no bearing on the separate Human Medicines Regulations 2012 framework under which unlicensed compounds are lawfully supplied for in vitro research use. Retatrutide's own regulatory position is unchanged: it remains an investigational, injectable triple-receptor peptide with a targeted Q1 2027 BLA filing in the US and no UK marketing authorisation of any kind, as covered in our retatrutide research overview.
What this news does confirm is how crowded the licensed oral GLP-1 segment has become in 2026: three branded tablets now hold or are pursuing UK/EU authorisation, while retatrutide's investigational, injectable, multi-receptor programme continues on an entirely separate research and regulatory track.
Velox Peptides does not stock orforglipron or semaglutide. This compound is supplied as a research reagent only. It is not a medicine and has not been evaluated by the MHRA or FDA for use in our products. Not for human or veterinary use. See our Research Use Policy and MHRA Statement.
References
- MHRA / GOV.UK. UK first in Europe to authorise orforglipron for weight management and type 2 diabetes. 10 August 2026. gov.uk
- pharmaphorum. UK first European country to approve Lilly's Foundayo. 2026. pharmaphorum.com
- Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. New England Journal of Medicine. doi:10.1056/NEJMoa2511774
- Eli Lilly and Company. Lilly's oral GLP-1, orforglipron, delivered superior blood sugar control and weight loss compared to oral semaglutide in head-to-head type 2 diabetes trial published in The Lancet. 2026. investor.lilly.com
- See Velox coverage: Retatrutide FDA & MHRA Approval Timeline, tracking the separate, unlicensed, investigational status of retatrutide.
Frequently Asked Questions
What did the MHRA approve on 10 August 2026?
The MHRA authorised Foundayo (orforglipron), Eli Lilly's oral small-molecule GLP-1 receptor agonist, for weight management in adults with a BMI of 30 or above (or 27-30 with a weight-related comorbidity) alongside diet and exercise, and separately for improving glycaemic control in adults with insufficiently controlled type 2 diabetes. This made the UK the first country in Europe to authorise the tablet.
What clinical trial data supported the approval?
The obesity indication draws on ATTAIN-1 (New England Journal of Medicine), where the highest studied dose (36mg) produced a mean 11.2% body-weight reduction at 72 weeks versus 2.1% with placebo. The diabetes indication draws on ACHIEVE-3 (The Lancet, n=1,698), a head-to-head trial in which orforglipron 36mg reduced A1C by 2.2 percentage points and body weight by 9.2% at 52 weeks, versus 1.4 points and 5.3% with oral semaglutide 14mg.
How is orforglipron different from oral semaglutide and from retatrutide?
Orforglipron is a non-peptide small molecule that activates only the GLP-1 receptor and needs no fasting or water-timing rules, unlike peptide-based oral semaglutide, which requires an absorption enhancer and strict dosing conditions. Retatrutide is a separate, unlicensed, injectable peptide that activates three receptors (GIP, GLP-1 and glucagon) and remains in Eli Lilly's investigational TRIUMPH Phase 3 programme; it has no oral formulation and no MHRA approval of any kind.
Is Foundayo available on the NHS?
Not yet. A Lilly spokesperson said Foundayo is expected to launch in the UK later in August 2026 through private prescription and pharmacist-led Patient Group Direction services. NICE guidance on NHS use is due on 18 November 2026, and there is no confirmed NHS availability or price ahead of that.
Does this approval affect UK research-reagent supply of retatrutide or other peptides?
No. This is an MHRA marketing-authorisation decision for a licensed prescription medicine, governed by branded-drug licensing rules. It has no bearing on the separate Human Medicines Regulations 2012 framework under which unlicensed compounds are lawfully supplied as in vitro research reagents. Velox Peptides does not stock orforglipron or semaglutide; it supplies retatrutide strictly as an HPLC-verified research reagent, not a medicine.